ArticleThe international journal of cardiovascular imaging2026
Echocardiographic Pulmonary to Left Atrial Ratio (ePLAR) as novel non-invasive parameter for elevated pulmonary vascular resistance in adults with unrepaired atrial septal defect.
Article in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Electrocardiogram and Pulmonary Hypertension: When Occam'S Razor Fails.Echocardiography (Mount Kisco, N.Y.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accurate evaluation of pulmonary vascular resistance (PVR) is critical for evaluating operability and guiding management in adults with unrepaired atrial septal defect (ASD). Non-invasive echocardiographic markers, such as the echocardiographic Pulmonary to Left Atrial Ratio (ePLAR), calculated by dividing the peak tricuspid regurgitation velocity (TR Vmax) by the ratio of the transmitral E-wave to mitral annular e' velocity, may facilitate early risk stratification and reduce reliance on invasive procedures. Eighty-nine adult patients with unrepaired ASD underwent comprehensive echocardiography and right heart catheterization. ePLAR and additional echocardiographic parameters were measured, and their ability to identify elevated PVR (≥5 Wood Units, WU) was assessed through correlation and receiver operating characteristic (ROC) analysis. PVR ≥ 5 group showed elevated ePLAR (0.41 vs. 0.29, p < 0.0001. ePLAR showed moderate ability to predict elevated PVR (AUC 0.754). The TR Vmax/ right ventricular outflow tract velocity-time integral (RVOT VTI) and TR Vmax²/RVOT VTI ratio demonstrated stronger discrimination (AUC 0.907 and 0.929). DeLong's test confirmed TR Vmax/RVOT VTI superiority (p = 0.0147). TRVmax/ right ventricular global longitudinal strain (RV GLS) shown to be an ineffective measure (AUC 0.265, p > 0.05). ePLAR is a practical, novel non-invasive echocardiographic parameter for identifying elevated pulmonary vascular resistance in adults with unrepaired ASD. With high sensitivity and independent predictive value, ePLAR is suitable for initial screening and risk stratification, potentially reducing unnecessary invasive testing and improving clinical decision-making.
Indexed as
Identifiers
41549188What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.